Compare AbbVie Inc (ABBV) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Amgen, Inc. — how do they compare? AbbVie Inc trades at $247.67 (market cap $441.94B), while Amgen, Inc. trades at $415.92 (market cap $224.14B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | AMGN | |
|---|---|---|
Market Cap | $441.94B | $224.14B |
Sector | Health | Health |
52-Week High | $263.58 | $417.20 |
52-Week Low | $197.38 | $271.18 |
Enterprise Value | $506.19B | $267.45B |
Dividend Yield | 2.77% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
